Lyon: Upgrades Jiangxi Zhengbang Technology (02268.HK) target price to HK$70.7, reiterates "outperform" rating.

According to the Wise Capital APP, Lyon released a research report stating that it holds a long-term positive view on the pharmaceutical industry alliance (02268.HK) and reiterated its "outperform" rating. The target price was raised from 47.3 Hong Kong dollars to 70.7 Hong Kong dollars. The forecast for revenue and net profit for the years 2025 to 2027 has been raised by 7% to 8% and 13% to 17% respectively. It is currently predicted that revenue for the years 2025 to 2027 will increase by 45%, 31%, and 27% respectively.